Search

Displaying results 4051 - 4060 of 10000 in total
  1. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  2. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  3. Drug

    Sucralose

    go.drugbank.com/drugs/DB15049
    Investigational

    Sucralose is an artificial sweetener used as a sugar substitute.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Ticarcillin

    go.drugbank.com/drugs/DB01607
    ApprovedVet approvedWithdrawn

    An antibiotic derived from penicillin similar to carbenicillin in action.

  5. Drug

    Pipobroman

    go.drugbank.com/drugs/DB00236
    Approved

    An antineoplastic agent that acts by alkylation.

  6. Drug

    Eldecalcitol

    go.drugbank.com/drugs/DB05295
    Investigational

    Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.

  7. Drug

    Thymol

    go.drugbank.com/drugs/DB02513
    ApprovedInvestigational

    A phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. … It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)

  8. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

  9. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  10. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    [L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … In addition, patients with LAL deficiency typically develop dyslipidemia, which itself contributes to a number of adverse cardiovascular outcomes.